Previous in vitro studies in breast cancer cell lines have shown that PI3K/AKT signaling can activate MMP-9 (50, 51), the MMP-9 promoter contains an NF-κB binding site (52), and siRNA inhibition of STAT3 in breast cancer cells could suppress MMP-9 (53). This evidence concerns the gene AKT1 and breast carcinoma.